Ligand Pharmaceuticals (LGND) FCF Margin (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted FCF Margin of 93.7% for Q1 2026, up 22.33% sequentially from 76.59% in Q4 2025, and up 15030.0% YoY from N/an in Q1 2025.
Ligand Pharmaceuticals (LGND) FCF Margin (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported FCF Margin for 17 years, with the latest figure at 93.7% in Q1 2026.
- Quarterly FCF Margin rose 15030.0% year-over-year to 93.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 44.91% (up 1684.0% YoY) and the FY2025 annual result came in at 18.33%, down 3864.0% from the prior year.
- FCF Margin rose to 93.7% in Q1 2026 per LGND's latest filing, from 76.59% in the prior quarter.
- Over five years, FCF Margin peaked at 129.08% in Q1 2022 and troughed at 56.6% in Q1 2025.
- A 5-year average of 46.2% and a median of 39.75% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2025 and 2026: FCF Margin slumped 11673 bps in 2025, then jumped 15030 bps in 2026.
- Over 5 years, FCF Margin stood at 77.76% in 2022, then slumped by 49 bps to 39.75% in 2023, then surged by 63 bps to 64.84% in 2024, then rose by 18 bps to 76.59% in 2025, then gained by 22 bps to 93.7% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 93.7%, 76.59%, and 11.34% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 37.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.67% |
| Mar 31, 2026 | 93.70% |
| Dec 31, 2025 | 76.59% |
| Sep 30, 2025 | 11.34% |
| Jun 30, 2025 | 33.60% |
| Mar 31, 2025 | -56.60% |
| Dec 31, 2024 | 64.84% |
| Sep 30, 2024 | 69.35% |
| Jun 30, 2024 | 31.08% |
| Mar 31, 2024 | 60.13% |
| Dec 31, 2023 | 39.75% |
| Sep 30, 2023 | 15.44% |
| Jun 30, 2023 | 6.83% |
| Mar 31, 2023 | 71.70% |
| Dec 31, 2022 | 77.76% |
| Sep 30, 2022 | 34.89% |
| Jun 30, 2022 | 25.84% |
| Mar 31, 2022 | 129.08% |
| Dec 31, 2021 | 47.22% |
| Sep 30, 2021 | 40.64% |